News & Investors
News
Lumicell Announces Promising Feasibility Trial Findings Using Pegulicianine in Gastrointestinal Cancer Patients
Pioneering real-time detection of cancer brings promise to enabling a more complete resection in gastrointestinal cancer surgery Newton, MA – Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for
Lumicell Announces U.S. Launch and First Commercial Use of LumiSystem™, Pioneering Real-Time Detection of Residual Breast Cancer During Lumpectomy
LumiSystem is the first and only fluorescence-guided imaging technology for breast cancer detection, enabling a more complete resection Newton, MA – Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging
Lumicell Announces Accomplished Healthcare Leader as New Member to Board of Directors
Independent director, Jim Alecxih, Chief Executive Officer of DH Medical joins Lumicell’s Board of Directors NEWTON, Mass., Jan. 6, 2025 – Lumicell, Inc., a privately held company focused on developing innovative
Lumicell Announces Poster Presentations at the 2024 San Antonio Breast Cancer Symposium Focused on Patient Benefit of Using LumiSystem™ During Lumpectomy
New data suggests that patients were satisfied with their cosmetic outcomes following the removal of suspicious tissue detected by fluorescence-guided imaging during lumpectomy surgery, and prefer to avoid a second
Lumicell Granted Permanent HCPCS Code for Intraoperative Fluorescence Imaging Margin Assessment
Permanent HCPCS code granted following U.S. FDA approval of LUMISIGHT™ (pegulicianine) and Lumicell™ Direct Visualization System (DVS), together referred to as LumiSystem™, with commercial availability in Q4 2024 NEWTON,
Lumicell’s LumiSystem™ Featured on Viewpoint with Dennis Quaid for New Episode on Fluorescence-Imaging Guidance During Lumpectomy Surgery
NEWTON, Mass., —Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, is thrilled to announce its upcoming collaboration for an
Lumicell Awarded Phase I NIH SBIR Contract to Develop Novel Flexible Endoscope for Fluorescence Imaging of LUMISIGHT™ to Detect Early Esophageal Lesions in Patients with Barrett’s Esophagus
Funding of approximately $400,000 will support development of novel endoscopic imaging platform combining far-red fluorescence and reflected light imaging to detect esophageal cancer NEWTON, Mass.,—Lumicell, Inc., a privately held company
CMS Grants Transitional Pass-Through Payment for LUMISIGHT™ (pegulicianine) and Increases Access for Patients with Breast Cancer
Transitional pass-through payment of optical imaging agent LUMISIGHT is effective October 1, 2024, as part of the hospital outpatient prospective payment system (OPPS) NEWTON, Mass.,—Lumicell, Inc., a privately held company
Lumicell Announces New Category III CPT® Code for Intraoperative Fluorescence Imaging Margin Assessment in Support of Market Launch
Add-on CPT code granted following U.S. FDA approval of LUMISIGHT™ (pegulicianine) and Lumicell™ DVS, together referred to as LumiSystem™, with commercial availability in Q4 2024 NEWTON, Mass., July 15, 2024—Lumicell,
Events
San Antonio Breast Cancer Symposium®,
December 10-14, 2024
Henry B. Gonzalez Convention Center
Investors
